COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge: A Single Center Analysis
Lung transplant (LTx) recipients are at high risk for COVID-19 related morbidity and mortality. Data regarding pre-exposure prophylaxis (PrEP) with tixagevimab-cilgavimab in this population are scarce. We therefore evaluated COVID-19 breakthrough infections and COVID-19 related complications after P...
Main Authors: | Saartje Demolder, Veronique Schaevers, Katrien Lagrou, Paul De Munter, Hanne Beeckmans, Geert M. Verleden, Laurent Godinas, Lieven J. Dupont, Pascal Van Bleyenbergh, Natalie Lorent, Robin Vos |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-01-01
|
Series: | Transplant International |
Subjects: | |
Online Access: | https://www.frontierspartnerships.org/articles/10.3389/ti.2024.12061/full |
Similar Items
-
Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study
by: Mohammed Kamal Nassar, et al.
Published: (2023-12-01) -
Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19
by: Nicolina Capoluongo, et al.
Published: (2023-10-01) -
Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients
by: Andrea Lombardi, et al.
Published: (2023-05-01) -
A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
by: Daniele Focosi, et al.
Published: (2022-09-01) -
Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple Sclerosis
by: Luke B. Elias, et al.
Published: (2023-12-01)